EDP-323 clinical trials
Also written EDP-323.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses EDP-323 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- EDP-323
- 3
Studies by the year they started
4 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses EDP-323 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge ModelCompletedPhase 2Enanta Pharmaceuticals, IncNCT06170242Written as EDP-323 Dose Regimen 1
- A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.CompletedPhase 1Enanta Pharmaceuticals, IncNCT06847464Written as EDP-323
- A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy ParticipantsCompletedPhase 1Enanta Pharmaceuticals, IncNCT06917508Written as EDP-323
- A Study of EDP-323 in Healthy SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT05587478Written as EDP-323